Benznidazole, itraconazole and their combination in the treatment of acute experimental Chagas disease in dogs

Cunha, Eleonora Lima Alves; Torchelsen, Fernanda Karoline Vieira da Silva; Cunha, Lucas Maciel; Oliveira, Maykon Tavares de; Reis, Levi Eduardo Soares; Fonseca, Kátia da Silva; Vieira, Paula Melo Abreu; Carneiro, Cláudia Martins; Lana, Marta de

doi:10.1016/j.mex.2019.10.007

Cited by 5 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12,13 Challenges with obtaining cure, preventing CCM, and adverse effects of antiparasitic medications have led to further research exploring alternative dosing strategies and other medical treatment options. 14,15 A combination of amiodarone and itraconazole has been described in the treatment of infected people and dogs with Chagas disease. 6,14 In 1 study, dogs that received this combination had improvement in clinical signs and lived an average of 7.5 months longer compared to a small control population.…”

mentioning

confidence: 99%

Antiparasitic treatment with itraconazole and amiodarone in 2 dogs with severe, symptomatic Chagas cardiomyopathy

Malcolm

Saunders

Vitt³

et al. 2022

Veterinary Internal Medicne

View full text Add to dashboard Cite

Chagas cardiomyopathy, caused by the protozoal parasite Trypanosoma cruzi, is characterized by arrhythmias, myocardial damage, heart failure, and sudden death. We describe 2 dogs with severe, symptomatic Chagas cardiomyopathy characterized by myocardial dysfunction and electrocardiographic abnormalities that were managed with a combination of cardiac medications and antiparasitic treatment with itraconazole and amiodarone. Both dogs died suddenly within 6 months of diagnosis. These cases highlight the need for early detection of Chagas disease in dogs and continued research to develop effective antiparasitic treatment protocols.

show abstract

mentioning

confidence: 99%

Antiparasitic treatment with itraconazole and amiodarone in 2 dogs with severe, symptomatic Chagas cardiomyopathy

Malcolm

Saunders

Vitt³

et al. 2022

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…The use of suboptimal doses or treatment length of BNZ in association with CYP51 inhibitors may maintain or increase the effectiveness of treatment by the synergistic or additive effect of compounds with different mechanisms of action or cellular targets. 56,118,119,150,[155][156][157][176][177][178][179][180] Similarly, allopurinol combined with low dose of BNZ had a positive interaction…”

Section: Drug Combination Therapymentioning

confidence: 98%

“… Combination led to an improvement in parasitemia reduction, and cardiac damage in infected mice. [ 176 , 178 ] [ 177 ] [ 157 ] BNZ/ketoconazole Combination induced a synergic effect in mice infected with CL and Y T. cruzi strains, but no differences were observed in Colombian strain-infected animals. [ 150 ] BNZ/fosravuconazole In vitro interaction was positive and in infected mice.…”

Section: Drug Combination Therapymentioning

confidence: 99%

See 1 more Smart Citation

Review on Experimental Treatment Strategies Against Trypanosoma cruzi

Mazzeti

Capelari-Oliveira

Bahia

et al. 2021

JEP

View full text Add to dashboard Cite

Chagas disease is a neglected tropical disease caused by the protozoan Trypanosoma cruzi . Currently, only nitroheterocyclic nifurtimox (NFX) and benznidazole (BNZ) are available for the treatment of Chagas disease, with limitations such as variable efficacy, long treatment regimens and toxicity. Different strategies have been used to discover new active molecules for the treatment of Chagas disease. Target-based and phenotypic screening led to thousands of compounds with anti- T. cruzi activity, notably the nitroheterocyclic compounds, fexinidazole and its metabolites. In addition, drug repurposing, drug combinations, re-dosing regimens and the development of new formulations have been evaluated. The CYP51 antifungal azoles, as posaconazole, ravuconazole and its prodrug fosravuconazole presented promising results in experimental Chagas disease. Drug combinations of nitroheterocyclic and azoles were able to induce cure in murine infection. New treatment schemes using BNZ showed efficacy in the experimental chronic stage, including against dormant forms of T. cruzi . And finally, sesquiterpene lactone formulated in nanocarriers displayed outstanding efficacy against different strains of T. cruzi , susceptible or resistant to BNZ, the reference drug. These pre-clinical results are encouraging and provide interesting evidence to improve the treatment of patients with Chagas disease.

show abstract

“…For these reasons, many efforts are being made in the search for new therapies. Combined treatments, mainly with BZ and other compounds, have been the most promising (Cunha et al, 2019;Echeverría et al, 2020), due to the synergistic mechanisms underlying combinatorial therapy (Zhang and Yan, 2019).…”

Section: Introductionmentioning

confidence: 99%

Differential tissue distribution of discrete typing units after drug combination therapy in experimental Trypanosoma cruzi mixed infection

Strauss¹,

Presti²,

Ramı́rez³

et al. 2021

Parasitology

View full text Add to dashboard Cite

show abstract

Benznidazole, itraconazole and their combination in the treatment of acute experimental Chagas disease in dogs

Abstract: Graphical abstract

Cited by 5 publications

References 12 publications

Antiparasitic treatment with itraconazole and amiodarone in 2 dogs with severe, symptomatic Chagas cardiomyopathy

Antiparasitic treatment with itraconazole and amiodarone in 2 dogs with severe, symptomatic Chagas cardiomyopathy

Review on Experimental Treatment Strategies Against Trypanosoma cruzi

Differential tissue distribution of discrete typing units after drug combination therapy in experimental Trypanosoma cruzi mixed infection

Contact Info

Product

Resources

About